AstraZeneca Acknowledges Vaccine Side Effect Resulting in Fatalities

Welcome to Extreme Investor Network, where we bring you the latest insights and updates on topics that matter most to investors around the world. Today, we are diving into the controversial topic of COVID-19 mRNA vaccines and their potential deadly side effects.

Recent developments have seen vaccine manufacturers and health agencies quietly admitting that their once-touted “safe and effective” vaccines may have lethal consequences. AstraZeneca, a major pharmaceutical company, is now facing a class-action lawsuit as evidence mounts against their COVID-19 vaccine.

One particularly alarming revelation is the admission that AstraZeneca’s vaccine can lead to Thrombotic Thrombocytopenic Syndrome (TTS), an autoimmune response that can result in serious health complications such as blood clots, internal bleeding, and even death. This information, hidden from the public, has now come to light as victims seek justice and accountability.

Related:  Head of Bayer Admits COVID-19 Vaccine is Gene Therapy

Infectious disease experts have highlighted the rarity of TTS occurring post-vaccination, with an incidence as low as one in 50,000. However, in a large population, this number becomes significant and raises concerns about the true risks associated with these vaccines.

The World Health Organization has also acknowledged the potential link between TTS and certain vaccines, urging vigilance and awareness among healthcare providers and the public. However, the information was buried in a 70-page document, raising questions about transparency and informed consent.

As victims seek damages and accountability from AstraZeneca, the broader implications of these revelations are alarming. The public, once assured of the safety and efficacy of these vaccines, is now grappling with the reality of potential risks and side effects.

Related:  Lululemon announces closure of Washington warehouse, resulting in layoffs for 128 employees

At Extreme Investor Network, we believe in providing our readers with comprehensive insights and analysis on critical issues affecting the investment landscape. Stay tuned for more updates and expert opinions on the ever-evolving economic landscape.

Source link